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Abstract
Epidermal growth factor receptor (EGFR) is an important oncoprotein that promotes cell growth and proliferation.
Dasatinib, a bcr-abl inhibitor, has been approved clinically for the treatment of chronic myeloid leukemia and dem-
onstrated to be effective against solid tumors in vitro through Src inhibition. Here, we disclose that EGFR degra-
dation mediated dasatinib-induced apoptosis in head and neck squamous cell carcinoma (HNSCC) cells. HNSCC
cells, including Ca9-22, FaDu, HSC3, SAS, SCC-25, and UMSCC1, were treated with dasatinib, and cell viability,
apoptosis, and underlying signal transduction were evaluated. Dasatinib exhibited differential sensitivities against
HNSCC cells. Growth inhibition and apoptosis were correlated with its inhibition on Akt, Erk, and Bcl-2, irrespective
of Src inhibition. Accordingly, we found that down-regulation of EGFR was a determinant of dasatinib sensitivity.
Lysosome inhibitor reversed dasatinib-induced EGFR down-regulation, and c-cbl activity was increased by dasatinib,
indicating that dasatinib-induced EGFR down-regulation might be through c-cbl–mediated lysosome degradation. In-
creased EGFR activation by ligand administration rescued cells from dasatinib-induced apoptosis, whereas inhibition
of EGFR enhanced its apoptotic effect. Estrogen receptor α (ERα) was demonstrated to play a role in Bcl-2 expression,
and dasatinib inhibited ERα at the pretranslational level. ERα was associated with EGFR in dasatinib-treated HNSCC
cells. Furthermore, the xenograft model showed that dasatinib inhibited HSC3 tumor growth through in vivo down-
regulation of EGFR and ERα. In conclusion, degradation of EGFR is a novel mechanism responsible for dasatinib-
induced apoptosis in HNSCC cells.
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Introduction
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase
(RTK) that belongs to the ErbB family. Once activated, EGFR trans-
duces signaling through the Ras-MAPK and PI3K-Akt pathways to pro-
mote cellular growth, proliferation, and survival [1]. Overexpression of
EGFR is frequently found in epithelial cancers. Studies in head and
neck squamous cell carcinoma (HNSCC) have shown that 80% to
100% of tumors have a high level of EGFR expression, which is corre-
lated with advanced stage of disease and poor prognosis [2–4]. EGFR-
targeted therapy, including monoclonal antibody and small molecules,
has led to advance of cancer treatment. Cetuximab, a monoclonal anti-
body against EGFR, demonstrates its clinical activity and has been
approved to be the first molecular targeted therapy for HNSCC [5,6].
Estrogen receptor (ER) is a nuclear receptor localized in both cytoplasm
and nucleus. ER exerts its nuclear activity by directly binding to DNA or
interacting with other transcription factors [7]. In addition, ER has rapid
cytoplasmic actions by interacting with other growth factor pathways
through kinase cascade, Ca2+, and other second messengers, which regu-
late gene transcription, cell proliferation, and cell survival [8,9]. There
are two different forms of the estrogen receptor, ERα and ERβ. ERα
expresses in endometrium, breast, ovary, and hypothalamus, whereas
ERβ in kidney, brain, bone, heart, lung, intestinal mucosa, prostate,
and vascular endothelium [10]. ERα is well known to be closely asso-
ciated with breast cancer carcinogenesis and prognosis and serves as
an important therapeutic target [11]. The significance of ERα signaling
in lung, esophagus, and HNSCC has also been reported [12–14]. In
HNSCC, ERα signaling interacts with EGFR to enhance cell growth
and invasion and confers poor clinical outcome [14].
HNSCC is a heterogeneous disease composed of oral, oropharyn-
geal, hypopharyngeal, and laryngeal squamous cell carcinoma. It is
closely associated with alcohol, betel nut, and cigarette. In Taiwan,
betel nut chewing is a problem of public health, and the incidence
of oral cancer is higher than that of Western countries. Despite ag-
gressive treatment, recurrence or metastasis is common, and most
patients will die within 1 year of disease recurrence [15]. Thus,
development of new therapies is urgent.
Dasatinib is a protein kinase inhibitor targeting bcr-abl, the hallmark
of chronic myeloid leukemia, and has been clinically approved to treat
chronic myeloid leukemia [16]. Dasatinib also exhibits a broad spectrum
of protein kinase inhibition including c-kit, platelet-derived growth factor
receptor, ephA2, and Src. Because Src is an oncoprotein closely associated
with solid tumor progression, metastasis, and poor outcome, dasatinib
has been reported to inhibit the growth, migration, and invasion of
non–small cell lung cancer (NSCLC) and HNSCC cells [17–19]. How-
ever, dasatinib exerts limited activities against NSCLC and HNSCC in
clinical trials despite consistent Src inhibition [20,21], implicating that
there are mechanisms beyond Src inhibition responsible for the efficacy
of dasatinib. In our study, degradation of EGFR was seen in dasatinib-
sensitive but not dasatinib-resistant HNSCC cells. The role of EGFR
was further validated in dasatinib-induced apoptosis. In addition, ERα
played a role and was correlated with EGFR to regulate dasatinib-
induced apoptosis. We demonstrated a novel mechanism responsible
for dasatinib-induced apoptosis in HNSCC.
Materials and Methods
Cell Culture
Ca9-22 was provided by Dr. Hsin-Ming Chen (Graduate Institute
of Oral biology, College of Medicine, National Taiwan University)
in 2009. SAS was provided by Dr. Han-Chung Wu (Institute of
Cellular and Organismic Biology, Academia Sinica) in 2010. HSC3
was provided by Dr. Kwang-Yu Chang (National Health Research
Institutes) in 2010. UMSCC1 was provided by Dr. Thomas Carey
(University of Michigan) in 2009. SCC-25 and FaDu were purchased
from Bioresource Collection and Research Center (Taiwan) in 2010.
Ca9-22, FaDu, HSC3, UMSCC1, and SAS cells were maintained in
Dulbecco modified Eagle medium supplemented with 10% fetal bovine
serum. SCC-25was cultured in 50%HamF-12medium, 50%Dulbecco
modified Eagle medium supplemented with 0.5 μg/ml hydrocortisone,
and 10% fetal bovine serum. Cells were incubated in a 37°C humidi-
fied incubator under an atmosphere of 5% CO2 in air. Cells were
checked daily by morphology and were tested to be Mycoplasma-free
by 4′,6-diamidino-2-phenylindole staining within the last 6 months.
Materials
Dasatinib (Sprycel) was kindly provided by Bristol Myers Squibb
pharmaceuticals (Princeton, NJ). Erlotinib (Tarceva) was kindly pro-
vided by Roche pharmaceuticals (Madison, WI). Lactacystin and
NH4Cl were purchased from Sigma-Aldrich (St Louis, MO). All ex-
perimental drugs were dissolved in dimethyl sulfoxide (DMSO; Sigma
Chemical Co). Anti–phospho-Akt, phosphor-Erk, phosphor-EGFR,
Bcl-2, Bcl-XL, Mcl-1, BAX, BAK, caspase 3, and caspase 9 were pur-
chased from Cell Signaling Technology (Denver, MA). Anti-Akt,
Erk, actin, EGFR, ERα, and MET were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
MTT Assay
Cell viability is determined using the MTT assay. Cells were
plated in triplicate in 96-well plates and treated with increasing con-
centrations of dasatinib. After 48 hours of incubation, cell growth
was measured using 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma) colorimetric method. The blue
MTT formazan precipitate was then dissolved in 100 μl of DMSO.
The absorbance at 550 nm was measured on a multiwell plate reader.
Cell viability was expressed as a percentage of control. Data are
shown as the mean ± SEM of three independent experiments.
Western Immunoblot Analysis
After treatment with specific drugs, total cell lysates were prepared
and subjected to SDS-PAGE using 7.5% or 10% running gels. West-
ern blot analysis was done as previously described [22]. Immunoblots
were quantitated using ImageJ software (version 1.44; National Insti-
tutes of Health, Bethesda, MD).
Flow Cytometry
Cell cycle and apoptosis were evaluated by flow cytometry. After
treating with the specific agents, HNSCC cells were trypsinized,
washed in phosphate-buffered saline (PBS), and centrifuged at
1000 rpm for 5 minutes. Then the cells are fixed with 75% ethanol
and frozen in −20°C. After washing with PBS twice, the cells are sus-
pended in 500 μl of solution containing propidium iodide and RNA-
ase. Flow cytometry was performed using BD FACSCalibur cytometer
with CellQuest Software (San Jose, CA). Apoptosis is determined by
the sub-G1 ratio in the cell cycle analysis.
Immunofluorescence Confocal Microscopy
HSC3 and SAS cells were cultured on glass coverslips and were
treated with dasatinib 1 μM or DMSO for 24 hours. Cells were fixed
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with 2% paraformaldehyde in PBS for 15 minutes and permeabilized
with 1%Triton X-100 in PBS for 15minutes. Cells were incubated with
anti-EGFR antibody (dilution, 1:100) and anti–lysosomal-associated
membrane protein 1 (LAMP-1) antibody (dilution, 1:100) for 1 hour.
Secondary antibody was applied to anti-EGFR antibody for 1 hour. For
labeling DNA, cells were stained with 4′,6-diamidino-2-phenylindole
(10 μg/ml) for 20 minutes. Cells were imaged on a Leica SP5 confocal
microscope with ×40 oil objective (Leica, Buffalo Grove, IL). Laser lines
of 488 and 543 nm were used for sequential excitation. Brightness and
contrast of the images were adjusted in PhotoShop CS (Adobe Systems
Incorporated, San Jose, CA).
Preparation and Infection of shEGFR–Expressing Lentivirus
Briefly, 6 μg of pCMV-dR8.91, 3 μg of pMD2.G, and 9 μg of pLKO-
shLuciferase and pLKOshEGFR were cotransfected into HEK293T cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The supernatants
containing infectious shLuciferase or shEGFR1 lentivirus were collected
on day 3 after transfection and stored at −80°C. For lentivirus infection,
2 × 105 HNSCC cells were infected with shLuciferase or shEGFR lenti-
virus at a multiplicity of infection of 1. The short hairpin RNA (shRNA)
sequence of EGFR isCCGGGCTGCTCTGAAATCTCCTTTACTC-
GAGTAAAGGAGATTTCAGAGCAGCTTTTTG. The shRNA
sequence of luciferase is CCGGCAAATCACAGAATCGTCGTAT-
CTCGAGATACGACGATTCTGTGATTTGT-TTTTG.
Real-time Polymerase Chain Reaction
Total RNA was isolated from HNSCC cells using TRIzol reagent
(Life Technologies, Camarillo, CA). Reverse transcription reaction was
performed using 2 μg of total RNA, which was reverse transcribed
into complementary DNA using oligo dT primer. Real-time poly-
merase chain reaction (PCR) was performed with complementary
DNA samples using the ABI Prism 7900 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA). Primers were as follows:
EGFR (forward primer, 5′-TTCCTCCCAGTGCCTGAAT-3′;
reverse primer, 5′-GGTTCAGAGGCTGAT-TGTGAT-3′), ERα
(forward primer, 5′CTCCTAACTTGCTCTTGGACAG 3′; reverse
primer, 5′TCG-GTTCCGC ATGATGAATC 3′), and actin (for-
ward primer, 5′-CCAACCG-CGAGAAGATGA-3′; reverse primer,
5′-TCCATCACGATGCCAGTG-3′). Data were normalized by the
actin housekeeping gene detection.
Subcutaneous Ectopic Xenograft Tumor Model
Eighteen male NCr athymic nude mice (4 weeks of age) were ob-
tained from the National Laboratory Animal Center (Taipei, Taiwan).
At the age of 6 weeks, 3 × 106 HSC3 cells (suspended in 0.1 ml of PBS
and mixed with 0.1 ml of Matrigel) were inoculated subcutaneously in
the rear left flank. Dasatinib was dissolved in citrate buffer (pH = 3.1).
When tumors reached 100 mm3, mice were randomized to receive oral
dasatinib (n = 9, 80 mg/kg) or vehicle (n = 9, citrate acid) 5 d/wk for
4 weeks. Tumor volume is calculated using the formula V (mm3) =
ab2 / 2, where a is the length and b is the width of the tumor.
Statistical Analysis
Quantitative data are presented as means ± SD from three inde-
pendent experiments. In the animal study, tumor growth data are
reported as mean tumor volume ± SE. The significance of differences
was evaluated with two-tailed Student’s t test. P < .05 was considered
statistically significant. The SPSS software (Windows version 11.5;
SPSS, Inc, Chicago, IL) was used for statistical analysis.
Results
Differential Sensitivities of HNSCC Cells to Dasatinib
We first evaluate the growth-inhibitory effect of dasatinib on six
HNSCC cell lines including Ca9-22, FaDu, HSC3, SAS, SCC-25, and
UMSCC1. By MTT assay, median inhibitory concentrations (IC50)
ranged from 280 nM to more than 10 μM (Table 1). Dasatinib exhib-
ited a significant growth-inhibitory effect on Ca9-22, HSC3, SCC-25,
and UMSCC1 cells but not FaDu and SAS cells (Figure 1A). Therefore,
six HNSCC cells are classified into dasatinib-sensitive and -resistant
cells by their IC50 (Table 1).
The sub-G1 fraction was analyzed by cell cycle analysis to determine
the apoptotic effect induced by dasatinib after 48 hours of treatment.
Dasatinib induced apoptosis in Ca9-22, HSC3, and SCC-25 cells,
whereas this was not observed in UMSCC1, FaDu, and SAS cells
(Figure 1B). Similar results were seen in the down-regulation of Bcl-2
and cleavage of pro–caspase 3 in Ca9-22, HSC3, and SCC-25 but
not in UMSCC1, FaDu, and SAS cells (Figure 1C).
The expression of proapoptotic BAX and BAK proteins and anti-
apoptotic Bcl-2, Mcl-1, and Bcl-XL proteins was further examined
to explore the mechanism of dasatinib-induced apoptosis. The de-
creased expression of Bcl-2 by dasatinib in sensitive HSC3 was seen
(Figure 1D), whereas the level of proapoptotic and other antiapoptotic
proteins was not affected. In dasatinib-resistant SAS cells, all test pro-
teins were not affected.
Inactivation of Akt and Erk but Not Src Correlated with
Dasatinib Sensitivity
The interaction of Src and RTK is well characterized that RTK
may act both upstream and downstream of Src [23]. PI3K-Akt
and Ras-MAPK(Erk) pathways, which regulate cellular growth, pro-
liferation, and survival, are downstream of RTK [24]. Therefore, the
activation of Src (phosphor-Src, p-Src, Y416), Akt (phosphor-Akt,
p-Akt, S473), and Erk (phosphor-Erk, p-Erk, T202/Y204) was evalu-
ated after treatment with dasatinib for 24 hours. Inactivation of Src as
well as Akt and Erk in a dose-dependent manner was seen in dasatinib-
sensitive cells; however, only Src was inactivated in dasatinib-resistant
cells (Figure 2).
Down-regulation of EGFR Correlated with
Dasatinib Sensitivity
Given that inhibition of Akt and Erk was correlated with dasatinib
sensitivity, we examined the activities of membrane RTKs. EGFR
and c-MET are well-known membrane RTKs expressed in HNSCC,
which are closely associated with carcinogenesis and tumor progression
[14,25]. The activation of EGFR (phosphor-EGFR, p-EGFR, Y1068)
was inhibited in sensitive but not resistant cells, and similar results were
also seen in the expression of EGFR (Figure 3, A and B). However, the
Table 1. Phenotype Classification of HNSCC Cells.
Cell Name Site of Origin IC50 (μM) Phenotype
UMSCC1 Mouth floor 0.28 Sensitive
Ca9-22 Gingiva 0.45 Sensitive
SCC-25 Tongue 0.62 Sensitive
HSC3 Tongue 0.78 Sensitive
FaDu Pharynx >10 Resistant
SAS Tongue >10 Resistant
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effect of dasatinib on c-MET activation (phosphor-MET, p-MET,
Y1234/1235) was varied and not correlated with its sensitivity in
HNSCC cells (data not shown). Dasatinib-induced EGFR down-
regulation was further examined by confocal microscopy. Decreased
EGFR (red) expression was seen in dasatinib-sensitive HSC3 cells
but not resistant SAS cells (Figure 3C ). EGFR mRNA transcription
was examined by real-time PCR, and dasatinib had no effect on EGFR
mRNA transcription in sensitive or resistant cells (Figure 4B).
Dasatinib Downregulated EGFR through
Lysosomal Degradation
It is well known that c-cbl mediates EGFR ubiquitination fol-
lowed by its internalization and degradation in lysosome [26]. Pro-
teasome has also shown to play a role in EGFR degradation [27,28].
By confocal microscopy, the expression of LAMP-1 (green), which is
closely related to late endosome activity [29], was increased by dasa-
tinib in sensitive HSC3 but not resistant SAS cells (Figure 3C ).
Dasatinib-induced EGFR down-regulation was reversed by NH4Cl
(lysosome inhibitor) but not lactacystin (proteasome inhibitor) in
sensitive HSC3 and Ca9-22 cells (Figure 4A, lanes 4 and 5 ). C-cbl
activity (phosphor-774, Y774) was increased within 4 hours by dasa-
tinib (Figure 4C ), indicating that c-cbl–mediated lysosome degrada-
tion might play a role in dasatinib-induced EGFR degradation.
EGFR Played a Role in Dasatinib-Induced Apoptosis
We further examined the role of EGFR as well as its downstream sig-
naling in dasatinib-induced apoptosis. Epidermal growth factor (EGF)
has been reported to activate EGFR and subsequently induce EGFR
degradation [29]. In sensitive HSC3 and Ca9-22 cells, dasatinib down-
regulated EGFR and inactivated its downstream Akt and Erk. Enhance-
ment of EGFR activation (p-EGFR, Y1068) by the addition of EGF
(10 ng/ml) abolished dasatinib-induced apoptosis as well as its inactiva-
tion of Akt and Erk (Figure 5, A and B, lanes 3 and 4). Nevertheless,
inhibition of EGFR activation by erlotinib (3 μM) enhanced dasatinib-
induced apoptosis as well as its inactivation of Akt and Erk in Ca9-22
and HSC3 cells (Figure 5, C and 5D, lanes 3 and 4). Knockdown of
Figure 1. Differential sensitivity of dasatinib in HNSCC cells. (A) MTT cell viability in HNSCC cells treated with dasatinib at the indicated
doses for 48 hours. Dot, mean (n= 3); bar, SD. (B) Sub-G1 analysis of HNSCC cells treated with dasatinib at the indicated dose for 48 hours.
Column, mean (n= 3); bar, SD. (C) Expression of Bcl-2 and cleavage of pro–caspase-3 in HNSCC cells treated with dasatinib at the indicated
doses for 48 hours. The expression of proteins was evaluated byWestern blot analysis. (D) Expression of Bcl-2, Bcl-XL, Mcl-1, Bax, and Bak
in dasatinib-sensitive HSC3 and -resistant SAS cells treated with dasatinib 1 μM for 24 hours. The expression of proteins was evaluated by
Western blot analysis. Representative of three independent experiments.
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Figure 2. Effect of dasatinib on Src, Akt, Erk, and Bcl-2. Inactivation of Src, Akt, and Erk in dasatinib-sensitive and -resistant cells treated
with dasatinib at the indicated doses for 24 hours. Upper panel, Western blot analysis of HNSCC cells. Representative of three independent
experiments. Lower panel, Immunoblots were quantitated to determine the ratio of p-Src to actin, p-Akt to actin, and p-Erk to actin.
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EGFR by shRNA also enhanced dasatinib-induced apoptosis and its
inhibition on Akt and Erk in HSC3 cells (Figure 5E , lanes 3 and 4).
In dasatinib-resistant SAS cells, dasatinib neither downregulated
EGFR nor inactivated the downstream Akt and Erk (Figure 5E , lanes 1
and 3). However, after EGFR was knocked down by shEGFR,
dasatinib could induce inactivation of Akt and Erk and apoptosis
(Figure 5F , lanes 3 and 4 ). Taken together, EGFR plays a role in
dasatinib-induced apoptosis.
Figure 3. Down-regulation of EGFR by dasatinib correlates with the sensitivity of dasatinib. (A, B) Expression of EGFR and downstream
Akt and Erk in dasatinib-sensitive (A) and -resistant (B) cells treated with dasatinib 1 μM for indicated intervals. Upper panel, Western blot
analysis of HNSCC cells. Representative of three independent experiments. Lower panel, Immunoblots were quantitated to determine
the ratio of EGFR to actin. (C) Evaluation of EGFR and LAMP-1 expression by fluorescence confocal microscopy. HNSCC cells were
treated with DMSO or dasatinib 1 μM for 24 hours.
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ERα Was Correlated with EGFR to Regulate
Dasatinib-Induced Apoptosis
ERα has been reported to regulate Bcl-2 expression through bind-
ing to estrogen response element in the promoters of Bcl-2 gene
[30,31]. Because dasatinib downregulated Bcl-2 in some HNSCC
cells (Figure 1C ), its effect on ERα was examined. Dasatinib down-
regulated ERα in sensitive but not resistant cells (Figure 6A). The
mechanism of ERα down-regulation was further investigated. Cyclo-
heximide, an mRNA translation inhibitor, decreased ERα level in a
time-dependent manner, which was reversed by the addition of dasa-
tinib (Figure 6B), indicating that dasatinib increased ERα stability. The
effect of dasatinib on ERα mRNA transcription was further examined.
Real-time PCR showed that dasatinib decreased ERα mRNA level in
sensitive cells but not resistant cells, indicating that dasatinib-induced
Figure 4. Mechanism of dasatinib-induced EGFR down-regulation. (A) Effect of lysosome inhibitor (NH4Cl, 20 mM) and proteasome
inhibitor (lactacystin, 10 μM) on dasatinib-induced EGFR down-regulation in HSC3 and Ca9-22 cells. Lower panel, Western blot analysis
of HNSCC cells. Upper panel, Immunoblots were quantitated to determine the ratio of EGFR to actin. Column, mean (n= 3); bar, SD; *P< .05
by paired Student’s t test. Representative of three independent experiments. (B) Effect of dasatinib on EGFR mRNA transcription in HSC3
and SAS cells treated with dasatinib 1 μM for designated intervals. (C) Effect of dasatinib on c-cbl activity in HSC3 and Ca9-22 cells. Rep-
resentative of three independent experiments.
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ERα down-regulation was attributed to the inhibition of ERα mRNA
transcription (Figure 6C).
The role of ERα in dasatinib-induced apoptosis was examined.
Addition of estradiol (E2) to dasatinib-treated Ca9-22 cells increased
Bcl-2 level and rescued cells from apoptosis (Figure W1A). The corre-
lation between EGFR and ERα was further examined. In sensitive cells,
addition of E2 to Ca9-22 cells partially reversed dasatinib-induced
EGFR down-regulation (Figure 6D, upper panel ), and activation of
Figure 5. Role of EGFR in dasatinib-induced apoptosis. (A, B) Effect of EGF addition to dasatinib (1 μM)-induced apoptosis and in-
activation of Akt and Erk in sensitive HSC3 (A) and Ca9-22 (B) cells. Cells were treated with dasatinib (1 μM, 0 hour) with or without
EGF (10 ng/ml, 24 hours [15 minutes before lysate collection]). (C, D) Effect of EGFR inhibition by erlotinib (3 μM) on dasatinib (1 μM)-
induced apoptosis and inactivation of Akt and Erk in sensitive HSC3 (C) and Ca9-22 (D) cells. (E, F) Effect of EGFR knockdown in sensitive
HSC3 (E) and resistant SAS (F) cells treated with dasatinib (1 μM). Cells were transfected with control shRNA or EGFR shRNA for 72 hours.
Cells were prepared for Western blot analysis after 24 hours of dasatinib treatment and for sub-G1 analysis after 48 hours of treatment.
Column, mean (n = 3); bar, SD; *P < .05 by paired Student’s t test. Representative of three independent experiments.
470 Dasatinib Degrades EGFR in HNSCC Cells Lin et al. Neoplasia Vol. 14, No. 6, 2012
Figure 6. Correlation of ERα and EGFR in dasatinib-treated HNSCC cells. (A) Expression of ERα in HNSCC cells treated with dasatinib at
1 μM for designated intervals. (B) Protein stability of ERα. Left, Expression of ERα in HSC3 cells treated with cycloheximide (10 μg/ml)
alone or in combination with dasatinib (1 μM) for designated intervals. Right, Immunoblots were quantitated to determine the ratio of
ERα to actin. (C) Effect of dasatinib (1 μM) on ERα mRNA transcription in dasatinib-sensitive HSC3 and -resistant SAS cells. Columns,
mean (n= 3); bars, SD; *P< .05 by paired Student’s t test. (D) Correlation of EGFR and ERα. Upper panel, Effect of E2 (1 nM) addition on
dasatinib (1 μM)-induced EGFR down-regulation and EGF (100 ng/ml) addition on dasatinib-induced ERα down-regulation in Ca9-22 cells.
Lower panel, Effect of EGFR inhibition by erlotinib (1 μM) or shRNA on ERα in SAS cells treated with dasatinib (1 μM). Cells were treated
with indicated agents for 24 hours. Immunoblots were quantitated to determine the ratio of EGFR to actin and ERα to actin.
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EGFR by EGF stimulation reversed dasatinib-induced ERα down-
regulation (Figure 6D, upper panel). Similarly, inhibition of EGFR ac-
tivation by erlotinib enhanced dasatinib-induced ERα down-regulation
in sensitive HSC3 cells (Figure W1B). Although ERα was not affected
by dasatinib in resistant SAS cells, it was inhibited by dasatinib in com-
bination with erlotinib or EGFR shRNA (Figure 6D, lower panel ). All
these results indicate that ERα is correlated with EGFR in dasatinib-
treated HNSCC cells.
Figure 7. In vivo effect of dasatinib on xenograft nude mice. (A) Antitumor effect of dasatinib on HSC3 tumors. Line, mean (n = 9); bars,
SE; *P < .05 by unpaired Student’s t test. (B) Left panel, Photograph of representative nude mice treated with vehicle or dasatinib. Right
panel, Comparison of tumor weight in two groups after the 4-week treatment. Column, mean (n = 9); bars, SE; *P < .05 by unpaired
Student’s t test. (C) Expression of EGFR and ERα in vehicle- or dasatinib-treated HSC3 tumors. Left, Western blot analysis of EGFR, ERα,
and p-Src in HSC3 tumors. The homogenates of four representative tumors treated with vehicle or dasatinib (80 mg/kg) for 28 days were
analyzed. Right, Immunoblots were quantitated to determine the ratio of EGFR to actin, ERα to actin, and p-Src to actin. Column, mean
(n = 4); bars, SE; *P < .05 by unpaired Student’s t test; NS, not significant. (D) Schematic illustration of the effect of dasatinib-induced
EGFR and ERα down-regulation.
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Effect of Dasatinib on HNSCC Xenograft Tumor
To confirm possible clinical implications, the in vivo effect of
dasatinib on HNSCC xenograft tumors was assessed. HSC3 cells
were subcutaneously injected into dorsal part of nude mice. Vehicle
(citrate buffer) or dasatinib at a dose of 80 mg/kg was orally given
5 d/wk for 4 weeks. Dasatinib significantly inhibited HSC3 tumor
growth (Figure 7, A and B; unpaired Student’s t test, P < .05). Ulcer-
ative wound and eschar formation were observed in dasatinib-treated
tumors, which might be attributed to treatment-related tumor necrosis.
All mice tolerated this treatment well without significant toxicity and
had stable body weights. In addition, dasatinib-treated HSC3 tumors
showed inhibition of Src and down-regulation of EGFR and ERα
(Figure 7C , Student t test, P < .05), indicating that both EGFR
and ERα played critical roles in the antitumor effect of dasatinib
in vivo.
Discussion
Molecular targeting therapy has become a relevant strategy in cancer
treatment within the past decade, in which proper patient selection by
predictive biomarkers leads to the success. For example, overexpression
of HER2 on trastuzumab treatment of breast cancer, distinct EGFR
mutation on gefitinib treatment of NSCLC, and wild type k-ras on
cetuximab treatment of colorectal cancer have been the paradigms of
predictive biomarkers for molecular targeted therapy [32–34]. Dasatinib
exerts limited clinical activity in unselected recurrent HNSCC patients
(0% objective response and 16.7% stable disease) despite consistent Src
inhibition [20,21]. We found that degradation of EGFR mediated
dasatinib-induced apoptosis in HNSCC cells. In addition, ERα was
associated with EGFR in dasatinib-treated HNSCC cells. Our study
not only demonstrated a new mechanism responsible for dasatinib-
induced apoptosis in HNSCC cells but also provided a molecular basis
to explore the dasatinib-sensitive cellular feature and predictive bio-
marker. Complexities of cell signaling in advanced cancer including re-
current HNSCC may result in the activation of feedback mechanisms.
Therefore, the combination of molecular targeted therapy is a rational
approach. We found that EGFR was differentially degraded by dasati-
nib, providing the basis for combination of dasatinib with EGFR inhib-
itor to treat HNSCC. Dasatinib, in combination with cetuximab, was
well tolerated in patients with solid tumors [35], and clinical trial is
ongoing. A pharmacodynamic study shows that Src activity is inhibited
by dasatinib (at a dosage of 100 mg/d) rapidly but recovered within 6 to
12 hours [21]. Because dasatinib 100 mg/d is well tolerated [21], dose
escalation is a possible strategy to overcome the recovery of Src activity.
Akt and Erk are signal hubs from membrane RTK [24]. Because
Akt and Erk were inactivated by dasatinib, the activation of EGFR
and c-MET, well-known RTKs in HNSCC [14,25], was examined.
Dasatinib not only inhibited EGFR activation but also downregulated
EGFR expression in sensitive but not resistant cells. Its inhibition on
c-MET was variable and not correlated with the sensitivity. Sen et al.
[36] reported that inhibition of c-MET activation was the determinant
of dasatinib in HNSCC, and they found the contribution of EGFR to
c-MET activation. The association of EGFR and c-MET has also been
reported in NSCLC, in which MET amplification leads to acquired
resistance of gefitinib and potentiates EGFR action independent of
the hepatocyte growth factor [37,38]. The association between EGFR
and c-MET in HNSCC cells deserves further investigation.
It is well known that c-cbl–mediated EGFR ubiquitination pro-
motes its degradation after ligand-induced activation [29]. We found
that late endosome activity was increased by dasatinib in sensitive cells,
and lysosome but not proteasome inhibitor reversed dasatinib-induced
EGFR degradation. Therefore, lysosome might play a role in dasatinib-
induced EGFR degradation. In addition, c-cbl activity was increased by
dasatinib, indicating that c-cbl–mediated lysosome pathway might be
responsible for dasatinib-induced EGFR degradation.
Cisplatin or gemcitabine has been reported to degrade EGFR in
sensitive HNSCC cells [39,40]. Increase in cisplatin- or gemcitabine-
induced cytotoxicity is seen with EGF addition, which enhances EGFR
degradation, whereas cytotoxicity is decreased with the addition of
gefitinib or erlotinib, which attenuates EGFR degradation [39,40].
By inhibiting EGFR degradation, addition of bortezomib decreases
the effect of cetuximab plus radiotherapy in HNSCC cells [41]. Our
recent work also shows that HDAC inhibitors induced cytotoxicity in
colorectal cancer cells through down-regulation of EGFR [42]. There-
fore, degradation of EGFR plays a critical role in anticancer treatment.
The status of cell cycle also has an impact on the effect of chemotherapy
in combination with EGF or EGFR inhibitor (gefitinib or erlotinib).
Because gemcitabine cytotoxicity is S phase–dependent and EGFR in-
hibitor induces G1 arrest [43], gemcitabine cytotoxicity is enhanced by
the addition of gefitinib after gemcitabine but is attenuated by gefitinib
before gemcitabine [43]. EGF can accelerate cell cycle progression to
potentiate gemcitabine cytotoxicity [43]. In the present study, cell cycle
acceleration by EGF addition reversed apoptosis induced by dasatinib,
which induces G1 arrest [19], whereas erlotinib inducing G1 arrest en-
hanced the effect of dasatinib. Erlotinib also inhibits EGFR activity,
and EGF addition activates EGFR, indicating that EGFR activity rather
than EGFR per se might determine dasatinib-induced apoptosis.
Up-regulation of antiapoptotic proteins might play a role to pro-
tect HNSCC cells from dasatinib-induced apoptosis. We found that
dasatinib induced growth inhibition but not apoptosis in UMSCC1
cells, in which inactivation of Akt and Erk but up-regulation of Bcl-2
were seen. Up-regulation of Bcl-2 might play a protective role from
apoptosis despite inactivation of Akt and Erk in UMSCC1 cells. In
addition, Src inhibition in some HNSCC cells leads to activation of
STAT3, which upregulates its downstream antiapoptotic Bcl-XL and
Mcl-1 proteins [44–46]. In our study, dasatinib did not affect the expres-
sion of Bcl-XL or Mcl-1 in either sensitive HSC3 or resistant SAS cells,
indicating that STAT3 activation might not occur in these cells.
We found a negative correlation between Bcl-2 expression and
dasatinib-induced apoptosis. Bcl-2 has been reported to be regulated by
ERα through its nuclear action [30,31]. Although protein stability of
ERα was increased by dasatinib, ERα was downregulated by dasatinib
through inhibition of mRNA transcription. The increased ERα protein
stability might be attributed to dasatinib-induced Src inhibition because
ERα degradation was promoted by Src activation [47]. Addition of
estrogen upregulated Bcl-2 and attenuated apoptosis, validating the role
of ERα in dasatinib-induced apoptosis. The crosstalk between ERα and
RTK family receptors is best characterized in breast cancer. HER2 acti-
vation leads to the resistance of hormonal therapy, and ERα signal-
ing attenuates the antitumor effect of HER2 inhibition [48]. Recently,
estrogen has been reported to be associated with early and late carcino-
genesis of HNSCC, and ERα works in concert with EGFR to promote
cellular growth and invasion and confers poor prognosis of HNSCC
[14,49]. We found that ERα was correlated with EGFR in dasatinib-
treated HNSCC cells, supporting the association between EGFR and
ERα in HNSCC.
In conclusion, we demonstrate that degradation of EGFR medi-
ates dasatinib-induced apoptosis in HNSCC cell. Our study also dis-
closes a new mechanism responsible for apoptosis, which provides a
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molecular framework to explore the predictive biomarker of dasatinib
in HNSCC.
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Figure W1. (A) Effect of E2 (1 nM) addition on dasatinib (1 μM)-induced apoptosis and Bcl-2 down-regulation in sensitive Ca9-22 cells.
Cell lysateswere prepared forWestern blot analysis after 24 hours of treatment, and cells were prepared for sub-G1 analysis after 48 hours of
treatment. Columns, mean (n= 3); bars, SD; *P< .05 by paired Student’s t test. (B) Effect of EGFR inhibition by erlotinib (1 μM) on dasatinib
(1 μM)-induced ER down-regulation in HSC3 cells for 24 hours.
